Sixty-six per cent provide coverage for GLP-1 drugs for diabetes only, while 17 per cent provide coverage for both diabetes and weight loss, according to a recent survey from the International Foundation of Employee Benefit Plans

CrossRef Targeting magnesium homeostasis: a novel therapeutic strategy for liver diseases Lili Ji, Hanhan Yu, Ruwen Wang, Hongmei Yan, Xiaofeng Yin, Shanshan Guo, Ru Wang Frontiers in Nutrition .2026;[Epub] CrossRef The Role of Butyrate in People with Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Metabolic Comorbidities: A Systematic Review Alicia Gonzlez-Gonzlez, Virginia Soria-Utrilla, Mara Isabel Fontalba-Romero, Mara ngeles Nez-Snchez, Antonio Adarve-Castro, Mara Isabel Queipo-Ortuo, Bruno Ramos-Molina, Jos Ignacio Martnez-Montoro, Jos Carlos Fernndez-Garca Current Obesity Reports .2026;[Epub] CrossRef Creatinine-to-body weight ratio as an independent predictor of hepatic steatosis severity in metabolic dysfunction-associated steatotic liver disease: a cross-sectional study Xiaoning Sun, Xiaozhong Wang, Ayesha Younas, Shuanghu Wang, Muhammad Sohail, Jiaojian Lv, Zuxiu Huang, Yunxiao Liu BMC Gastroenterology .2026;[Epub] CrossRef Metabolic liver imaging: What you need to know Luigi Asmundo, Amirkasra Mojtahed, Samay Prakash, Theodore T

Podczas tworzenia dzieci rozwijay sprawno manualn, kreatywno oraz wyobrani
Trials Commun
Moreover, several clinical studies show that glycemia improves when doses are increased but with unacceptable rates of gastrointestinal adverse events 16,17,18 , suggesting that maximum benefits from GLP-1R agonism are in fact not realized with current treatments